



# *The Mind and the Moon*

MY BROTHER'S STORY,  
THE SCIENCE OF OUR BRAINS,  
AND THE SEARCH FOR OUR PSYCHES

*Daniel Bergner*



*An Imprint of HarperCollins Publishers*

THE MIND AND THE MOON. Copyright © 2022 by Daniel Bergner. All rights reserved. Printed in the United States of America. No part of this book may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in critical articles and reviews. For information, address HarperCollins Publishers, 195 Broadway, New York, NY 10007.

HarperCollins books may be purchased for educational, business, or sales promotional use. For information, please email the Special Markets Department at [SPsales@harpercollins.com](mailto:SPsales@harpercollins.com).

Ecco® and HarperCollins® are trademarks of HarperCollins Publishers.

First Ecco hardcover published 2022

FIRST EDITION

*Designed by Paula Russell Szafranski*

Library of Congress Cataloging-in-Publication Data has been applied for.

ISBN 978-0-06-300489-4

22 23 24 25 26 LSC 10 9 8 7 6 5 4 3 2 1

## NOTES ON SOURCES

The personal stories I have told are based strictly on extensive interviews, immersion in worlds both shared and unshared, and my own memories. (The book's stories and science are also underpinned by countless interviews with people who do not appear on the page.) The lawyer I call David asked for a minor measure of privacy; his actual name is not David, and I have slightly altered limited details to protect him. The man I have called Ellis requested a name change only. Caroline's clients have also been given pseudonyms.

What follows are citations—chapter by chapter; chronologically within each chapter—for the science and history I write about. The citations do not represent all the tunnels of research that inform the book, but they will provide readers with substantiation and a start to further reading.

Special mention is warranted for the histories of psychiatry contained in two sources, Anne Harrington's *Mind Fixers* and Robert Whitaker's *Mad in America* and *Anatomy of an Epidemic*. Varied criticisms have been made of these two writers, yet it is an

understatement to say that the depth of the histories they have compiled is invaluable.

## CHAPTER ONE

Caleb Gardner and Arthur Kleinman, “Medicine and the Mind—The Consequences of Psychiatry’s Identity Crisis,” *New England Journal of Medicine* 381, no. 18 (October 31, 2019): 1697ff.

Ronald Fieve, *Moodswing* (New York: William Morrow, 1975).

For statistics on adult use of psychotropics: Thomas J. Moore and Thomas R. Mattison, “Adult Utilization of Psychiatric Drugs and Differences by Age, Sex, and Race,” *Journal of the American Medical Association (JAMA) Internal Medicine* 177, no. 2 (February 2017): 274ff. Also, Debra J. Brody and Qiuping Gu, “Antidepressant Use Among Adults: United States, 2015–2018,” *National Center for Health Statistics Data Brief* no. 377 (September 2020). For the forty-fold increase in bipolar diagnosis: Carmen Moreno et al., “National Trends in the Outpatient Diagnosis and Treatment of Bipolar Disorder in Youth,” *Archives of General Psychiatry* 64, no. 9 (September 2007): 1032ff. For rates among college students: Marcia R. Morris et al., “Use of Psychiatric Medication by College Students: A Decade of Data,” *Pharmacotherapy* 41, no. 4 (April 2021): 350ff.

For ADHD rates of diagnosis: “National Prevalence of ADHD and Treatment: Information on Children and Adolescents, 2016,” from the website of the Centers for Disease Control and Prevention, [www.cdc.gov/ncbddd/adhd/features/national-prevalence-adhd-and-treatment.html](http://www.cdc.gov/ncbddd/adhd/features/national-prevalence-adhd-and-treatment.html). Also, for further research references and summary of debated ADHD numbers: [evolvvetreatment.com/blog/diagnosing-adhd-by-country/](http://evolvvetreatment.com/blog/diagnosing-adhd-by-country/). Also, Michel Lecendreux et al., “Prevalence of Attention Deficit Hyperactivity Disorder and Associated Features Among Children in France,” *Journal of Attention Disorders* 15, no. 6 (August 2011): 516ff. Also, Raphaëlle Beau-Lejdstrom et al., “Latest Trends in ADHD Drug Prescribing Patterns in Children in the UK: Prevalence, Incidence, and Persistence,” *British Medical Journal* 6 (June 2016).

For the study of antidepressant prescribing patterns in the U.S., UK, and Germany: Carol L. Link et al., “Diagnosis and Management of Depression in Three Countries: Results from a Clinical Vignette Factorial Experiment,” *Primary Care Companion for CNS Disorders* 13, no. 5 (2011).

For country-by-country prescription patterns: “Something Startling Is Going on with Antidepressant Use Around the World,” *Business Insider*, February 4, 2016.

## CHAPTER TWO

On King George: Ida Macalpine and Richard Hunter, *George III and the Mad-Business* (London: Allen Lane, Penguin Press, 1969). Also, the website of the Royal Collection Trust, Georgian Papers Program: [www.rct.uk/collection/georgian-papers-programme/medical-papers-relating-to-george-iii](http://www.rct.uk/collection/georgian-papers-programme/medical-papers-relating-to-george-iii), and here: [georgianpapersprogramme.com/wp-content/uploads/2018/10/greville.pdf](http://georgianpapersprogramme.com/wp-content/uploads/2018/10/greville.pdf). On Francis Willis’s asylum: Frederick Reynolds, *The Life and Times of Frederick Reynolds*, vol. 1 (Philadelphia: W. C. Carey and I. Lea, 1826), 87.

On Benjamin Rush and his tranquilizer chair: Stephen Fried, *Rush: Revolution, Madness, and Benjamin Rush, the Visionary Doctor Who Became a Founding Father* (New York: Crown, 2018), 448. On Benjamin Franklin and electroshock: Tom G. Bolwig and Max Fink, “Electrotherapy for Melancholia: The Pioneering Contributions of Benjamin Franklin and Giovanni Aldini,” *Journal of ECT* 25, no. 1 (March 2009): 15ff. Also, Bart Lutters and Peter J. Koehler, “Franklin and Ingenhousz on Cranial Electrotherapy,” *World Neurology*, posted March 1, 2016.

On William Cullen: Robert Whitaker, *Mad in America: Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill* (New York: Crown, 2002). On the unnamed doctor quoted just after Cullen, see Emil Kraepelin, *One Hundred Years of Psychiatry* (New York: Philosophical Library, 1962); Kraepelin, one of the fathers of modern psychiatry, quotes this doctor only as “Shneider.” On Joseph Guislain’s Chinese Temple, see his *Traité sur l’Aliénation Mentale et sur les Hospices des Aliénés* vol. 1 (1826). Also, [wellcomecollection.org/works/v7t4wd5r](http://wellcomecollection.org/works/v7t4wd5r). On the story of Guislain’s winning entry in the king’s competition: [museumofthemind.org.uk/projects/european-journeys/bios/joseph-guislain](http://museumofthemind.org.uk/projects/european-journeys/bios/joseph-guislain). Also, Whitaker, *Mad in America*. The story of Phineas Gage and other widely known figures and events in the history of psychiatry and neuroscience will go without citation here. For the quotation from the director of a pastoral refuge, see Whitaker, *Mad in America*. On Nellie Bly’s exposé: Nellie Bly, *Ten Days in a Mad-House* (New York: Ian L. Munro, 1887). The story of Henry Cotton is from Whitaker,

*Mad in America*. The story of the Chicago surgeon—Bayard Holmes—is from Anne Harrington, *Mind Fixers: Psychiatry's Troubled Search for the Biology of Mental Illness* (New York: W. W. Norton & Co., 2019).

On Sigmund Freud: Peter D. Kramer, *Freud: Inventor of the Modern Mind* (New York: HarperCollins, 2006). Also, Mark Solms, “Freud, Luria, and the Clinical Method,” *Psychoanalysis and History* 2, no. 1 (2000): 76ff. Also, Sigmund Freud, “Lecture XXXIII: Femininity,” *New Introductory Lectures on Psychoanalysis*, 1933.

On the history of the lobotomy: Whitaker, *Mad in America*, and Harrington, *Mind Fixers*. Also, these short films on the procedure and Walter Freeman: [www.youtube.com/watch?v=TjPwETslJyc](http://www.youtube.com/watch?v=TjPwETslJyc) and [www.youtube.com/watch?v=Wo2Md95kTCA](http://www.youtube.com/watch?v=Wo2Md95kTCA).

On the risk of tardive dyskinesia with Risperdal: Stephen R. Marder and Tyrone D. Cannon, “Schizophrenia,” *New England Journal of Medicine* 381, no. 18 (October 31, 2019): 1753ff. A drug released in 2017, Ingrezza, attempts to treat tardive dyskinesia. Its revenues are around one billion dollars per year. About half of those taking the drug can expect some partial reduction of symptoms, according to research published by the drug’s manufacturer, Neurocrine Biosciences, at [ingrezzahcp.com](http://ingrezzahcp.com).

On the rise of psychoanalysis during and after World War II and on the biological manifesto of 1978: Harrington, *Mind Fixers*.

Donald Goff’s analysis in favor of antipsychotics as the default long-term treatment for psychosis: Donald C. Goff et al., “The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia,” *American Journal of Psychiatry* 174, no. 9 (September 2017): 840ff. A contrary perspective: Lex Wunderlink et al., “Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction /Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-year Randomized Clinical Trial,” *JAMA Psychiatry* 70, no. 9 (September 2013): 913ff.

## CHAPTER FOUR

On Thorazine as well as the minor tranquilizers: Harrington, *Mind Fixers*, and Whitaker, *Mad in America* and *Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America* (New York: Crown, 2010). The Pfizer executive’s testimony can be found in the

record of the Senate hearings, p. 10243ff: [books.google.com/books?id=Vt00Zlv38bsC&pg=PA10241&lpg=PA10241&dq=haskell+weinstein+pfizer&source=bl&ots=i4lwXWS\\_BM&sig=ACfU3U0kF-fDwd3coBgLYgJvkZ7SmR2nAA&hl=en&sa=X&ved=2ahUKewij57-987vtAhWuxVkKHYWuDGYQ6AEwDXoECBAQAg#v=onepage&q=haske1l%20weinstein%20pfizer&f=false](https://books.google.com/books?id=Vt00Zlv38bsC&pg=PA10241&lpg=PA10241&dq=haskell+weinstein+pfizer&source=bl&ots=i4lwXWS_BM&sig=ACfU3U0kF-fDwd3coBgLYgJvkZ7SmR2nAA&hl=en&sa=X&ved=2ahUKewij57-987vtAhWuxVkKHYWuDGYQ6AEwDXoECBAQAg#v=onepage&q=haske1l%20weinstein%20pfizer&f=false).

The NIMH study of Thorazine and two other antipsychotics: “Phenothiazine Treatment in Acute Schizophrenia,” *Archives of General Psychiatry* 10, no. 3 (1964): 246ff.

On media coverage of Thorazine: “Aid for the Mentally Ill,” *New York Times*, June 26, 1955; “Tranquil Wards Show Drugs’ Help,” *New York Times*, January 29, 1956; “Pills for the Mind,” *Time*, March 7, 1955.

On President Kennedy: The website of the John F. Kennedy Presidential Library and Museum, [www.jfklibrary.org/learn/about-jfk/jfk-in-history/john-f-kennedy-and-people-with-intellectual-disabilities](http://www.jfklibrary.org/learn/about-jfk/jfk-in-history/john-f-kennedy-and-people-with-intellectual-disabilities). Also, “President Seeks Funds to Reduce Mental Illness,” *New York Times*, February 6, 1963.

On the development of Haldol: Bernard Granger and Simona Albu, “The Haloperidol Story,” *Annals of Clinical Psychiatry* 17, no. 1 (2005): 137ff.

On antipsychotic dosages: S. P. Segal et al., “Neuroleptic Medication and Prescription Practices with Sheltered-Care Residents: A 12-year Perspective,” *American Journal of Public Health* 82, no. 6 (June 1992): 846ff. Also, G. T. Reardon et al., “Changing Patterns of Neuroleptic Dosage Over a Decade,” *American Journal of Psychiatry* 146, no. 6 (June 1989): 726ff.

On the Oprah interview and fallout: “Free Expression or Irresponsibility,” *New York Times*, September 22, 1987.

The Pulitzer-winning series on psychotropic medication: Jon Franklin, “The Mind Fixers,” *Baltimore Sun*, July 23–31, 1984.

LSD’s role: Harrington, *Mind Fixers*.

NAMI’s IRS filing: Whitaker, *Anatomy of an Epidemic*.

On Zyprexa: “Eli Lilly Said to Play Down Risks of Top Pill,” *New York Times*, December 17, 2006. Also, “U.S. Drug Agency Investigating Accuracy of Lilly’s Zyprexa Data,” *New York Times*, April 25, 2007. Also, “Lilly Said to Be Near \$1.4 Billion U.S. Settlement,” *New York Times*, January 14, 2009. Also, Jim Gottstein, *The Zyprexa Papers* (Anchorage: Jim Gottstein, 2020). On Zyprexa and foster children: Thomas I. Mackie et al., “Antipsychotic Use Among Youth in Foster Care Enrolled in a Specialized Managed Care Organization Intervention,” *Journal of the American*

*Academy of Child and Adolescent Psychiatry* 59, no. 1 (January 2020): 166ff. Also, Meredith Matone et al., “Antipsychotic Prescribing to Children: An In-Depth Look at Foster Care and Medicaid Populations,” Policy Lab, The Children’s Hospital of Philadelphia, Spring 2015. Also, “Why Are So Many Foster Care Children Taking Antipsychotics?” *Time*, November 29, 2011.

On Joseph Biederman: Whitaker, *Anatomy of an Epidemic*.

The account of the marketing and side effects of Risperdal owes a great debt to Steven Brill’s series “America’s Most Admired Lawbreaker,” *Huffington Post*, 2015.

The NIMH study of second-generation antipsychotics (stating, “Neurologic Side Effects: There were no significant differences among the groups in the incidence of extrapyramidal side effects, akathisia, or movement disorders as reflected by rating-scale measures of severity”): Jeffrey A. Lieberman et al., “Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia,” *New England Journal of Medicine* 353, no. 12 (September 22, 2005): 1209ff.

## CHAPTER FIVE

David’s reading about benzodiazepine withdrawal: Baylissa Frederick, *Recovery and Renewal: Your Essential Guide to Overcoming Dependency and Withdrawal from Sleeping Pills, Other Benzodiazepine Tranquillisers, and Antidepressants* (RRW Publishing, 2017). Also, Heather Ashton, *Benzodiazepines: How They Work and How to Withdraw*, online at [www.benzo.org.uk/manual/bzcha01.htm](http://www.benzo.org.uk/manual/bzcha01.htm).

The Nathan Kline quotation is as quoted in Harrington, *Mind Fixers*.

The theory of deficient neurotransmitters: J. J. Schildkraut, “The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence,” *American Journal of Psychiatry* 122, no. 5 (November 1965): 509ff.

An example of the chemical-imbalance ads: [www.adforum.com/creative-work/ad/player/23659/christmas-tree/prozac](http://www.adforum.com/creative-work/ad/player/23659/christmas-tree/prozac). On the marketing of antidepressants: Nathan P. Greenslit and Ted J. Kaptchuk, “Antidepressants and Advertising: Psychopharmaceuticals in Crisis,” *Yale Journal of Biology and Medicine* 85, no. 1 (March 2012): 153ff.

The research on serotonin levels is as described and cited in Whitaker, *Anatomy of an Epidemic*, except for the University of Texas research: P. L. Delgado and F. A. Moreno, “Role of Norepinephrine in Depression,” *Journal of Clinical Psychiatry* 61, suppl. 1 (2000): 5ff.



The 2021 NIMH language about chemical imbalance: [www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=In%20other%20words%2C%20antidepressants%20improved,within%20one%20or%20two%20weeks](http://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=In%20other%20words%2C%20antidepressants%20improved,within%20one%20or%20two%20weeks).

On the placebo effect: Irving Kirsch, *The Emperor's New Drugs: Exploding the Antidepressant Myth* (New York: Random House, 2009). Peter D. Kramer, *Ordinarily Well: The Case for Antidepressants* (New York: Farrar, Straus and Giroux, 2016). Also, Marcia Angell, "The Epidemic of Mental Illness: Why?", *New York Review of Books*, June 23, 2011. On the rise in use of antidepressants 2009–2018: Debra J. Brody and Qiuping Gu, "Antidepressant Use Among Adults: United States, 2015–2018," *National Center for Health Statistics Data Brief* no. 377 (September 2020).

On McKinsey & Company: "McKinsey Advised Purdue Pharma How to 'Turbocharge' Opioid Sales, Lawsuit Says," *New York Times*, February 1, 2019.

On antidepressant withdrawal: "Many People Taking Antidepressants Discover They Cannot Quit," *New York Times*, April 7, 2018. Also, "How to Quit Antidepressants: Very Slowly, Doctors Say," *New York Times*, March 5, 2019. Also, Rachel Aviv, "The Challenge of Going Off Psychiatric Drugs," the *New Yorker*, April 1, 2019. Also, Abie Horowitz and David Taylor, "Tapering of SSRI Treatment to Mitigate Withdrawal Symptoms," *The Lancet Psychiatry* 6, no. 6 (June 2019): 538ff.

The 1997 report, produced by Eli Lilly, on "discontinuation syndrome": [www.baumhedlundlaw.com/documents/pdf/cymbalta-unsealed-docs/Exh-078-Journal-Clinical-Psychiatry-Supplement-Antidepressant-Discontinuation-Syndrome-Update-SSRIs-1997.pdf](http://www.baumhedlundlaw.com/documents/pdf/cymbalta-unsealed-docs/Exh-078-Journal-Clinical-Psychiatry-Supplement-Antidepressant-Discontinuation-Syndrome-Update-SSRIs-1997.pdf).

## CHAPTER SIX

The interrogation of Joan of Arc: [www.jeanne-darc.info/trials-index/the-examination-at-poitiers/](http://www.jeanne-darc.info/trials-index/the-examination-at-poitiers/).

## CHAPTER EIGHT

On connectivity: Esther M. Blessing et al., "Anterior Hippocampal–Cortical Functional Connectivity Distinguishes Antipsychotic Naïve First-Episode Psychosis Patients from Controls and May Predict Response to Second-Generation Antipsychotic Treatment," *Schizophrenia Bulletin* 46, no. 3 (May 2020): 680ff.

- On the learning and unlearning of fear: Daphne J. Holt et al., “Extinction Memory Is Impaired in Schizophrenia,” *Biological Psychiatry* 65, no. 6 (March 2009): 455ff.
- Goff’s journey with DCS, a sampling of papers: Donald C. Goff et al., “Dose-Finding Trial of D-cycloserine Added to Neuroleptics for Negative Symptoms in Schizophrenia,” *American Journal of Psychiatry* 152, no. 8 (August 1995): 1213ff. Also, Donald C. Goff and Joseph T. Coyle, “The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia,” *American Journal of Psychiatry* 158, no. 9 (September 2001): 1367ff. Also, Donald C. Goff, “D-Cycloserine: An Evolving Role in Learning and Neuroplasticity in Schizophrenia,” *Schizophrenia Bulletin* 38, no. 5 (September 2012): 936ff. Also, Erica D. Diminich, “D-cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions: A Randomized Clinical Trial,” *Schizophrenia Research* 222 (August 2020): 145ff.
- On possible causes of schizophrenia: Jeffrey A. Lieberman et al., eds., *The American Psychiatric Association Publishing Textbook of Schizophrenia* (Washington, D.C.: American Psychiatric Association Publishing, 2020). The Lieberman textbook is one source for the six percent chance of being diagnosed with schizophrenia if one biological parent has the condition. Also on possible causes, Rebecca Pinto et al., “Schizophrenia in Black Caribbeans Living in the U.K.: An Exploration of Underlying Causes of the High Incidence Rate,” *British Journal of General Practice* 58, no. 551 (June 2008): 429ff.

## CHAPTER TEN

- On Soteria’s history: Loren R. Mosher and Joyce Hendrix, *Soteria: Through Madness to Deliverance* (Loren R. Mosher, Joyce Hendrix, 2004).
- On the WHO research: Assen Jablensky et al., “Schizophrenia: Manifestations, Incidence, and Course in Different Cultures,” *Psychological Medicine Monograph Supplement* 20 (1992). On the critiques: Alex Cohen et al., “Questioning an Axiom: Better Prognosis for Schizophrenia in the Developing World?” *Schizophrenia Bulletin* 34, no. 2 (March 2008): 229ff. And a counter to the critiques: Assen Jablensky and Norman Sartorius, “What Did the WHO Studies Really Find?” *Schizophrenia Bulletin* 34, no. 2 (March 2008): 253ff.

The Dutch research: Lex Wunderlink et al., “Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction /Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-year Randomized Clinical Trial,” *JAMA Psychiatry* 70, no. 9 (September 2013): 913ff.

On brain atrophy: “Using Images to Understand How the Brain Works,” *New York Times*, September 16, 2008.

On schizophrenia and violence: Harry J. Steadman et al., “Violence by People Discharged from Acute Psychiatric Inpatient Facilities and by Others in the Same Neighborhoods,” *Archives of General Psychiatry* 55, no. 5 (May 1998): 393ff. Also, Seena Fazel et al., “Schizophrenia and Violence: Systematic Review and Meta-analysis,” *PLOS Medicine* 6, no. 8 (August 2009). Also, Paul S. Appelbaum, “Violent Acts and Being the Target of Violence Among People With Mental Illness—the Data and Their Limits,” *JAMA Psychiatry* 77, no. 4 (April 2020): 345ff. Also, Daniel Whiting et al., “Violence and Mental Disorders: A Structured Review of Associations by Individual Diagnoses, Risk Factors, and Risk Assessment,” *Lancet Psychiatry* 8 (February 2021): 150ff.

The OnTrackNY manual: [www.ontrackny.org/portals/1/Files/Resources/MedicalManual\\_2015.01.21.pdf](http://www.ontrackny.org/portals/1/Files/Resources/MedicalManual_2015.01.21.pdf).

The coverage of psychedelics as medication: “The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same,” *New York Times*, May 5, 2021. On the trial with no significant difference: Robin Carhart-Harris, “Trial of Psilocybin Versus Escitalopram for Depression,” *New England Journal of Medicine* 384, no. 15 (April 15, 2021): 1402ff.

## CHAPTER ELEVEN

The writing of Marius Romme: Marius A. Romme and Alexandra D. Escher, “Hearing Voices,” *Schizophrenia Bulletin* 15, no. 2 (1989): 209ff.